Pathological Femoral Fracture due to Osteoporosis and Hypophosphatemic Osteomalacia Following Adefovir Therapy in a Patient with Chronic Hepatitis B

BATIBAY S., GELER KÜLCÜ D., MESCİ N., RUHİ B. Ç., ŞAHİN Z., GÜNDOĞDU H.

TURK OSTEOPOROZ DERGISI, cilt.24, ss.59-62, 2018 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Vaka Takdimi
  • Cilt numarası: 24
  • Basım Tarihi: 2018
  • Doi Numarası: 10.4274/tod.04796
  • Dergi Adı: TURK OSTEOPOROZ DERGISI
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.59-62
  • Anahtar Kelimeler: Adefovir dipivoxil, hypophosphatemia, osteomalacia, osteoporosis, fracture, DIPIVOXIL, SAFETY
  • Recep Tayyip Erdoğan Üniversitesi Adresli: Evet

Özet

Adefovir dipivoxil (ADV) is a nucleotide analogue used in the chronic hepatitis B treatment. Proximal renal tubular dysfunction is one of the adverse effects of this agent and characterized with hypophosphatemia and osteomalacia. However, reduced bone mineral density with fracture due to ADV therapy has not been reported before. We aimed to report a 55-year-old male patient with proximal femur fracture who developed hypophosphatemic osteomalacia while using low dose of adefovir (10 mg/day) for chronic hepatitis B treatment for 10 years.